MedPath

Rivazin

Brand Name: Rivazin

Generic Name: Rivastigmine

Active
Registration Number

DR-XY47762

Dosage Form

Transdermal Patch

Issuance Date

March 2, 2022

Expiry Date

March 2, 2027

Product Information

Philippine FDA product specifications and classification details

Product Specifications

Dosage Strength18 mg/10 cm2 (9.5mg/24 hours)
PackagingAluminum foil pouch package (PAN: Polyacryl-nitrile material)

Classification

C
Classification
Prescription Drug (RX)
Philippine FDA Classification

Active Ingredients (1)

Complete list of active ingredients in this pharmaceutical product.

RivastigmineActive
Monograph: Rivastigmine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

MedPath - Medical Intelligence Platform